<DOC>
	<DOCNO>NCT01639001</DOCNO>
	<brief_summary>This Phase III , Randomized , Open-label , Efficacy Safety Study Crizotinib single agent versus Chemotherapy Regimens ( Pemetrexed/Cisplatin Pemetrexed/Carboplatin ) First-Line ALK ( Anaplastic Lymphoma Kinase ) Positive East Asian Non-Small Cell Lung Cancer Patients . The objective study demonstrate Crizotinib superior first-line chemotherapy pemetrexed/cisplatin pemetrexed/carboplatin prolong Progression Free Survival ( PFS ) East Asian patient advance Non-Squamous NSCLC whose tumor harbor translocation inversion event involve ALK ( Anaplastic Lymphoma Kinase ) gene locus .</brief_summary>
	<brief_title>A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically cytologically proven diagnosis locally advance suitable local treatment , recurrent metastatic nonsquamous cell carcinoma lung . Positive translocation inversion event involve ALK gene locus . No prior systemic treatment locally advance metastatic disease . Patients brain metastasis treat neurologically stable least 2 week take medication contraindicate Exclusion Criteria Evidence personally sign date informed consent document willingness ability comply schedule visit , treatment plan , laboratory test , study procedure include completion patient report outcome [ PRO ] measure . Current treatment another therapeutic clinical trial . Prior therapy directly target ALK . Any follow within 3 month prior start study treatment : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , congestive heart failure , cerebrovascular accident include transient ischemic attack . Appropriate treatment anticoagulant permit . Ongoing cardiac dysrhythmias NCI CTCAE Grade &gt; =2 , uncontrolled atrial fibrillation grade , QTc interval &gt; 470 msec . Pregnancy breastfeed . Use drug food know potent CYP3A inducers/inhibitors Concurrent use drug CYP3A substrates narrow therapeutic index . Known HIV infection History extensive disseminated/bilateral know presence Grade 3 4 interstitial fibrosis interstitial lung disease , include history pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , interstitial lung disease , obliterative bronchiolitis , pulmonary fibrosis , history prior radiation pneumonitis . Other severe acute chronic medical condition ( include severe gastrointestinal condition diarrhea ulcer ) psychiatric condition , endstage renal disease hemodialysis , laboratory abnormality would impart , judgment investigator and/or sponsor , excess risk associate study participation study drug administration , would , therefore , make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crizotinib</keyword>
	<keyword>ALK positive</keyword>
	<keyword>ALK</keyword>
	<keyword>Anaplastic Lymphoma Kinase</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Frontline</keyword>
	<keyword>1L</keyword>
	<keyword>Previously Untreated</keyword>
	<keyword>East Asian</keyword>
	<keyword>Non-Squamous</keyword>
</DOC>